Heinz Gisslinger

Heinz Gisslinger

UNVERIFIED PROFILE

Are you Heinz Gisslinger?   Register this Author

Register author
Heinz Gisslinger

Heinz Gisslinger

Publications by authors named "Heinz Gisslinger"

Are you Heinz Gisslinger?   Register this Author

100Publications

4142Reads

35Profile Views

GDF-15 in solid vs non-solid treatment-naïve malignancies.

Eur J Clin Invest 2019 Nov 26;49(11):e13168. Epub 2019 Sep 26.

Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/eci.13168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899906PMC
November 2019

Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count.

Transl Res 2018 10 13;200:35-42. Epub 2018 Jun 13.

Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19315244183009
Publisher Site
http://dx.doi.org/10.1016/j.trsl.2018.05.009DOI Listing
October 2018

Austrian recommendations for the management of polycythemia vera.

Wien Klin Wochenschr 2018 Sep 19;130(17-18):535-542. Epub 2018 Jul 19.

Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-018-1359-3DOI Listing
September 2018

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Wien Klin Wochenschr 2018 Sep 24;130(17-18):495-504. Epub 2018 Jul 24.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-018-1365-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132876PMC
September 2018

Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.

Br J Haematol 2017 10 19;179(1):166-169. Epub 2016 Jul 19.

Division of Haematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14202DOI Listing
October 2017

Pre-PMF emerging as important subgroup of MPN.

Authors:
Heinz Gisslinger

Blood 2017 06;129(24):3142-3144

MEDICAL UNIVERSITY OF VIENNA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-04-777805DOI Listing
June 2017

Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

Am J Hematol 2017 05 4;92(5):417-419. Epub 2017 Mar 4.

Hematology division, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24684DOI Listing
May 2017

Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.

Eur J Haematol 2016 Dec 23;97(6):511-516. Epub 2016 May 23.

Division of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12759DOI Listing
December 2016

In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.

Eur J Haematol 2016 Dec 15;97(6):562-567. Epub 2016 Jun 15.

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12773DOI Listing
December 2016

Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

Haematologica 2016 12;101(12):e492

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.156448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479601PMC
December 2016

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

J Clin Oncol 2016 10;34(30):3609-3617

Cyrille Hulin, Bordeaux Hospital University Center, Bourdeaux; Philippe Rodon, Centre Hospitalier de Périgueux, Périgueux; Brigitte Pégourié, Centre Hospitalier Regional Universitaire, Grenoble; Laurent Garderet, Centre Hospitalier Universitaire (CHU) Hôpital St-Antoine, Paris; Isabelle Azais, CHU Institut National de la Santé et de la Recherche Médicale (INSERM); Xavier Leleu, Hôpital de la Milétrie, CHU INSERM, Poitiers; Margaret Macro, CHU de Caen, Caen; Bruno Royer, University Hospital, Amiens; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Andrew Belch, Cross Cancer Institute, Edmonton, Alberta; Chaim Shustik, Royal Victoria Hospital; Richard LeBlanc, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; Kevin Song, Vancouver General Hospital, Vancouver, British Columbia, Canada; Maria Teresa Petrucci, Azienda Policlinico Umberto I, University La Sapienza, Rome, Italy; Ulrich Dührsen, University Hospital of Essen, West German Cancer Center, Essen, Germany; Jin Lu, Peking University Institute of Hematology, People's Hospital, Beijing, China; Hannah Hunter, Derriford Hospital, Plymouth, United Kingdom; Richard Eek, Border Medical Oncology, Wodonga, Victoria, Australia; Heinz Gisslinger, Medizinische Universität Wien, Vienna, Austria; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Cristina Goncalves, Hospital de Santo Antonio-Porto, Porto, Portugal; Ken Romeril, Wellington Hospital, Wellington, New Zealand; Chantal Doyen, Université Catholique de Louvain (UCL), CHU UCL Namur, Yvoir; Fritz Offner, Universitair Ziekenhuis Gent, Ghent, Belgium; Nicolas Leupin, Celgene International, Boudry, Switzerland; Vanessa Houck, Guang Chen, and Annette Ervin-Haynes, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7295DOI Listing
October 2016

[In Process Citation].

Leuk Res 2016 05 26;44 Suppl 1. Epub 2016 Apr 26.

Deputy Chair of CEMPO (Central European Myeloproliferative Neoplasm Organization).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0145-2126(16)30070-4DOI Listing
May 2016

Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans.

Genome Biol 2016 Jan 29;17:14. Epub 2016 Jan 29.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13059-016-0873-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731934PMC
January 2016

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Blood 2015 Oct 10;126(15):1762-9. Epub 2015 Aug 10.

Laboratory for Immunological and Molecular Cancer Research, Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-04-637280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608390PMC
October 2015

Interleukin-10 inhibits autonomous myelopoiesis in patients with myelofibrosis.

Eur J Haematol 2015 Sep 7;95(3):239-43. Epub 2015 Jan 7.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12486DOI Listing
September 2015

Current and future treatment options for polycythemia vera.

Ann Hematol 2015 Jun 2;94(6):901-10. Epub 2015 Apr 2.

Johannes Wesling Academic Medical Center, Minden, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2357-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420843PMC
June 2015

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Haematologica 2015 Jun 3;100(6):757-67. Epub 2015 Apr 3.

INSERM UMR-S1197, Paul Brousse Hospital, Paris-Sud University, Villejuif, France INSERM UMS33, Paul Brousse Hospital, Paris-Sud University, Villejuif, France French Intergroup on Myeloproliferative Neoplasms (FIM), France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.118497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450621PMC
June 2015

Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis.

Am J Hematol 2014 Dec 27;89(12):1157-8. Epub 2014 Aug 27.

5th Department of Internal Medicine - Oncology/Hematology, Hospital Hietzing, Vienna, Austria; Ludwig Boltzmann Institute for Clinical Oncology, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23829DOI Listing
December 2014

Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia.

Eur J Haematol 2014 Aug 23;93(2):103-11. Epub 2014 Apr 23.

Division of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12307DOI Listing
August 2014

Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.

Am J Hematol 2014 Mar;89(3):344-6

Department of Hematology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23637DOI Listing
March 2014

High spontaneous granulocyte/macrophage-colony formation in patients with myelofibrosis.

Leuk Res 2014 Jan 14;38(1):116-20. Epub 2013 Oct 14.

5th Department of Internal Medicine - Oncology/Hematology, Hospital Hietzing, Vienna, Austria; Ludwig Boltzmann Institute for Clinical Oncology, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.10.003DOI Listing
January 2014

Somatic mutations of calreticulin in myeloproliferative neoplasms.

N Engl J Med 2013 Dec 10;369(25):2379-90. Epub 2013 Dec 10.

From CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (T.K., A.S.H., H.N., J.D.M., N.C.C.T., T.B., D.C., G.I.V., K.B., F.S., C.C., M. Six, A.S., C.B., G.S.-F., R.K.) and the Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna (H.G., B.G., M. Schalling, R.K.) - both in Vienna; and the Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo (E.R., D.P., C.M., I.C.C., E.S., V.F., C.E., L.M., C.P., M.C.), and the Department of Molecular Medicine, University of Pavia (L.M., M.C.) - both in Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1311347DOI Listing
December 2013

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.

Wien Klin Wochenschr 2013 Apr 28;125(7-8):196-9. Epub 2013 Mar 28.

Innere Medizin IV, Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, 4600 Wels, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-013-0345-zDOI Listing
April 2013

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Blood 2013 Mar 11;121(10):1720-8. Epub 2013 Jan 11.

Medical University of Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-07-443770DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591796PMC
March 2013

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Nat Genet 2009 Apr 15;41(4):450-4. Epub 2009 Mar 15.

Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.341DOI Listing
April 2009